U.S. stock market mid-session update: Jin Medical fell 13.31%, trading volume increased, market sentiment fluctuations attract attention

U.S. Stock Market Midday Update Jin Medical, down 13.31%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Boston Scientific up 3.16%. Based on recent key news: On January 20, Boston Scientific announced research results at the NANS 2026 conference, driving the stock price up. The company showcased its latest research findings at the conference, enhancing market confidence in its innovation capabilities, resulting in a 3.16% increase in stock price. Source: Public Technologies On January 19, Boston Scientific discussed the company's future strategy in a global data healthcare podcast, attracting investor attention. Company executives elaborated on the strategic planning for the coming years in the podcast, boosting market confidence in its long-term growth potential. Source: GlobalData Healthcare On January 18, analysts maintained a buy rating but did not include it in the top recommendations. Although Boston Scientific received a buy rating, it was not listed as a top investment choice by leading analysts, indicating market caution regarding its short-term performance. Source: MarketBeat The medical device industry has recently performed strongly, with significant capital inflows. INVO Fertility up 233.59%. Based on recent key news: On January 20, INVO Fertility participated in the Lytham Partners 2026 Investor Medical Summit, conducting an online fireside chat. Although the event has concluded, the delayed release of related news may have driven the stock price surge. The stock rose 316.05% in pre-market trading on Tuesday, following a slight increase the previous day. On January 20, INVO Fertility's debt-to-equity ratio improved, indicating that management is more cautious in its use of leverage. This enhances the company's financial flexibility, reduces the pressure that expansion efforts may place on cash flow, and provides more room for pursuing inorganic growth. TipRanks believes that if clinic acquisitions can improve utilization and operational leverage, and management can control costs during network expansion, INVO may gradually move towards a more sustainable economic model. The U.S. market is experiencing increased volatility, and risks need to be monitored. Penumbra up 1.34%. Based on recent key news: On January 20, the diversification of merger and acquisition trends in the medical industry boosted market confidence. A Chinese biotech company formed a joint venture with a multinational pharmaceutical company to share global rights, promoting industry consolidation and enhancing market expectations, leading to an increase in Penumbra's stock price. On January 19, the company's strategic outlook at a global medical conference was positive, boosting investor sentiment. The CEO-led meeting detailed the company's future strategic layout, enhancing market confidence and promoting stock price growth On January 19, despite poor trading activity at the conference, the company showcased its future plans, attracting investor attention. The company presented its future development plans at the conference, and although trading activity was lackluster, it still drew investor interest, driving up the stock price. The merger and acquisition trend in the healthcare industry is diversifying, with significant capital inflows. Stocks ranked among the top in industry market capitalization Abbott fell by 0.77%. Based on recent news, On January 20, Abbott released its latest financial report, showing strong internal growth engines, including the continued promotion of the Libre diabetes platform and contributions from Volt technology. These factors supported analysts' buy ratings for Abbott. On January 18, Bernstein analyst Lee Hambright raised Abbott's target price from $150 to $154 and maintained an outperform rating, further boosting market confidence in the stock. On January 16, Bank of America Securities also maintained a buy rating on Abbott, giving a target price of $150, reflecting optimistic expectations for the company's future growth. The healthcare industry is performing well overall, with clear policy support